Anatomical-Clinical Base of Adenocarcinoma Pancreatic

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-16

Study Completion Date

2035-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biological and Clinical Database for Pancreatic Adenocarcinoma

NCT02818829

Pancreatic Adenocarcinoma

ACTIVE_NOT_RECRUITING

Prospective Monocentric Clinical-biological Database

NCT04136132

Pancreatic Cancer

RECRUITING NA

Onco-geriatric Database of Patients With Pancreatic Cancer

NCT02858141

Pancreatic Neoplasms

UNKNOWN

Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients

NCT05380414

Metastatic Pancreatic Cancer Advanced Pancreatic Cancer

RECRUITING NA

Development & Clinical Application of K-PaC Registry Version 2.0

NCT07171515

Pancreatic Cancer

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pancreatic cancer represents the fourth cause of death by cancer in Western countries. In over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic cancer remains the surgical exeresis. This one can only be suggested as a curative treatment in only 10 to 15% of cases. Besides, prevention or screening is difficult to set up due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice.

The research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. It is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy).

The present project aims to enrich with fresh tumor tissue and somatic genetic analysis the existing propective collection BACAP in order to support support future research projects on:

* the development of new diagnostic tools,
* understanding the development of tumors of the pancreas
* the development of new therapeutic targets
* understanding the response to chemotherapy…

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adenocarcinoma Carcinoma Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

collection of biological samples

Collection of biological samples including whole blood and micro-biopsy from tissue of pancreas

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or
* Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or
* Patient with pancreatic adenocarcinoma proven histologically and/or cytologically

Exclusion Criteria

* Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma
* Pregnant or breastfeeding patient

Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Barbara BOURNET, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Toulouse

Locations

Explore where the study is taking place and check the recruitment status at each participating site.